Kyprolis (carfilzomib) is a targeted therapy that’s used to treat a type of blood cancer called multiple myeloma. It’s usually given together with other medications such as lenalidomide (Revlimid) and dexamethasone. Kyprolis (carfilzomib) is given through the vein (intravenously, IV) at a provider’s office or infusion center once or twice a week. It might cause side effects like tiredness and low blood cell counts, and it has a risk of heart problems.
Kyprolis (carfilzomib) is a proteasome inhibitor. It works by attaching to proteins called proteasomes in multiple myeloma cancer cells. This blocks the proteasomes from properly breaking down other proteins that the cell no longer needs to keep the cell alive.
Multiple myeloma cancer cells make more proteins than normal cells. So when Kyprolis (carfilzomib) blocks how proteasomes work, the cancer cells can’t function correctly and usually die. As a result, the myeloma cells can’t grow and spread as well.
The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.
Note: These side effects were reported in people with multiple myeloma taking Kyprolis (carfilzomib) by itself. Side effects might differ for people taking Kyprolis (carfilzomib) along with other anticancer medications.
Contact your healthcare provider immediately if you experience any of the following.
Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur:
More common
Agitation
black, tarry stools
bleeding gums
bloating or swelling of the face, arms, hands, lower legs, or feet
blood in the urine or stools
blurred vision
burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
chest pain or tightness
confusion
decreased awareness or responsiveness
decreased urine output
difficult or labored breathing
difficulty with moving
dizziness
drowsiness
fast, slow, or irregular heartbeat
headache
hoarseness
hostility
irritability
loss of consciousness
lower back or side pain
muscle spasms (tetany) or twitching
numbness or tingling in the hands, feet, or lips
painful or difficult urination
pale skin
pinpoint red spots on the skin
pounding in the ears
rapid weight gain
seizures
severe sleepiness
tingling of the hands or feet
trembling
trouble breathing
ulcers, sores, or white spots in the mouth
unsteadiness or awkwardness
unusual bleeding or bruising
unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
unusual weight gain or loss
vomiting
Less common
Chills
continuing ringing, buzzing, or other unexplained noise in the ears
hearing loss
muscle pain or cramps
painful blisters on the trunk of the body
weakness in the arms, hands, legs, or feet
Rare
Dark urine
general feeling of discomfort or illness
light-colored stools
stomach pain, continuing
thickening of bronchial secretions
yellow eyes or skin
Incidence not known
Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
blindness
dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
fainting
joint pain, stiffness, or swelling
stomach pain
sweating
Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.
Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.
While Kyprolis (carfilzomib) is a medication that’s used to treat cancer, it’s not considered chemotherapy. Chemotherapy works by attacking any cell in the body that grows very quickly, which includes cancer cells. Kyprolis (carfilzomib) works in a different way. Instead of attacking cells that grow quickly, Kyprolis (carfilzomib) is a targeted therapy that blocks a specific protein in cells called a proteasome. Multiple myeloma cancer cells rely on proteasomes more than healthy cells to function. So when Kyprolis (carfilzomib) blocks proteasomes from working properly, the cancer cells can’t grow and spread as well.
Most guidelines recommend that you take a medication such as aspirin or Eliquis (apixaban) to prevent blood clots while you’re taking Kyprolis (carfilzomib). People with multiple myeloma are at higher risk for blood clots. In addition, some medications that might be included in your treatment plan can make your risk even higher. These medications not only include Kyprolis (carfilzomib) but also lenalidomide (Revlimid). Keep in mind that the decision to add a blood thinner to your treatment plan is something that you and your provider need to make together. Talk to your provider about whether or not you need to take a blood thinner while you take Kyprolis (carfilzomib).
It’s possible for you to develop tumor lysis syndrome while you’re taking Kyprolis (carfilzomib). People with multiple myeloma, especially those taking Kyprolis (carfilzomib) to treat the cancer, can be at risk for this complication. Tumor lysis syndrome occurs when cancer cells are rapidly destroyed and release what was inside them into the bloodstream. It can lead to high levels of potassium and uric acid in the blood, which can be harmful to your heart and kidneys. To lower your risk for tumor lysis syndrome, your provider will monitor you closely and give you extra fluids when you start Kyprolis (carfilzomib). They also might recommend other medications like allopurinol (Zyloprim) to prevent complications.
Possibly. Talk to your provider about whether Kyprolis (carfilzomib) is safe for you to take if you have heart problems. Some people who take Kyprolis (carfilzomib) have had heart problems, such as heart failure, changes in heart rhythm (arrhythmias), and heart attack. You might be at risk for heart problems during treatment if you are older than 75 years old, have had heart failure or a recent heart attack, or have heart rhythm problems. If your provider decides that you should take Kyprolis (carfilzomib), they might follow up with you more often to make sure it’s safe for you throughout treatment.
Some people might feel nauseous while they’re taking Kyprolis (carfilzomib). But this medication is actually less likely to cause nausea than other cancer medications. If you do feel nauseous while taking Kyprolis (carfilzomib), it’s usually mild. Let your provider know if you experience nausea during treatment. They might recommend medications such as ondansetron (Zofran) or prochlorperazine to help manage it.
Kyprolis (carfilzomib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Though uncommon, some people taking Kyprolis (carfilzomib) have developed heart problems such as heart failure and heart attack, which can be life-threatening. This can happen in people with or without a history of heart problems. Tell your provider if you have a history of heart problems before starting Kyprolis (carfilzomib) so they know to follow up with you more closely during treatment.
Let your provider know right away if you have any new swelling in your legs or trouble breathing at any time during treatment, regardless of your medical history. You might need to take a break from Kyprolis (carfilzomib) while your provider checks your heart. But call 911 right away if you have sudden chest pain or lose consciousness; this could be a medical emergency.
Some people taking Kyprolis (carfilzomib) have had kidney failure, which means your kidneys don’t work as well. You might not have symptoms when this happens, but your provider can identify problems with kidney function from lab test results. It’s important to go to your appointments to get your lab work done during treatment so that your provider can keep track of your kidney health. Contact your provider if you have symptoms of kidney problems, such as having less urine or feeling weak, confused, and nauseous.
Tumor lysis syndrome (TLS) is a complication that might happen when cancer cells are destroyed and release what was inside the cells into the bloodstream. This complication can be dangerous because it can lead to high levels of uric acid and potassium in the blood, which can cause problems with your kidneys and heart. You’re most at risk for TLS with the first one or two doses of Kyprolis (carfilzomib).
Your provider might give you extra fluids or medications such as allopurinol (Zyloprim) to prevent TLS. Your provider will also monitor your electrolyte levels very closely. If your lab results show signs of TLS, you might need to pause Kyprolis (carfilzomib) while you get treated for this complication.
Though rare, some people taking Kyprolis (carfilzomib) have had serious and sometimes life-threatening lung problems. Talk to your provider right away if you experience sudden or worsening cough, trouble breathing, very quick breathing, a rattling sound while breathing, or fever. You might have to pause or stop Kyprolis (carfilzomib) while your provider figures out what’s causing the lung problem.
Rarely, some people taking Kyprolis (carfilzomib) had a problem with the blood vessels in their lungs called pulmonary hypertension. This condition makes it harder for your heart to get blood to your lungs to pick up oxygen. Call your provider if you have trouble breathing or chest pain or if you feel lightheaded; these can be symptoms of pulmonary hypertension. You might need to take a break from the medication while your provider checks out the problem. You might have to stop taking it altogether if it’s confirmed that you have pulmonary hypertension.
Kyprolis (carfilzomib) can cause high blood pressure (also known as hypertension). Sometimes, high blood pressure can be managed with diet changes or medications. But other times, it can be difficult to control and can be dangerous. Your provider might ask you to check your blood pressure at home and keep a record of your readings. Seek medical help as quickly as possible if your blood pressure is over 180/120 or if you have symptoms such as sudden, severe headache; confusion; or weakness. You might not be able to take Kyprolis (carfilzomib) if you have high blood pressure that’s hard to manage.
People who take Kyprolis (carfilzomib) together with certain medications (such as lenalidomide (Revlimid)) are at higher risk for blood clots. Your provider might recommend that you take a blood thinner such as aspirin to prevent blood clots. Your provider will discuss with you about which blood thinner is most appropriate for you. Get medical help right away if you have symptoms of a blood clot, such as sudden swelling, redness, or warmth in one arm or one leg or sudden trouble breathing.
Some people have experienced reactions during or within 24 hours of a Kyprolis (carfilzomib) infusion. Symptoms of these infusion-related reactions can include fever, chills, trouble breathing, flushing, and face swelling. Typically, you’ll take a medication called dexamethasone before your Kyprolis (carfilzomib) infusion to prevent a reaction. Your nurse will keep an eye for reactions during each infusion. Seek medical attention as soon as possible if you develop these symptoms after an infusion.
Kyprolis (carfilzomib) can raise your risk for bleeding. In studies, cases of bleeding included nosebleeds, bleeding in the gut or lungs, and rarely, bleeding in the brain. Sometimes, bleeding is related to having low platelet counts, which can be caused by treatment with Kyprolis (carfilzomib). For this reason, your provider will closely check your platelet count with blood tests. Note that bleeding has also happened in people with normal platelet counts.
Tell your provider right away if you have any unusual bleeding. If you bleed or if your platelet count is low, your provider might briefly pause treatment and then restart the medication later at a lower dose when you’ve recovered. But sometimes, you’ll have to stop taking the medication permanently.
Some people taking Kyprolis (carfilzomib) have had blood test results showing high liver enzyme levels, which can suggest liver problems. Most people don’t feel any noticeable symptoms when this happens. Your provider will check your liver health on a regular basis to make sure this medication is still safe for you to take. If your liver labs are too high, your provider might need to pause or stop your treatment with Kyprolis (carfilzomib). Call your provider right away if you experience symptoms of liver problems, such as stomach pain, yellowish skin, or yellow around the whites of your eyes.
Rarely, people who’ve taken Kyprolis (carfilzomib) have developed blood conditions called thrombotic microangiopathies, which mean your red blood cells or platelets don’t work as well. Sometimes, your provider will notice that you have this condition from your lab test results before you have any symptoms. But seek medical attention right away if you have fever with bruising or red-purple rash on your skin, very pale skin, or bloody diarrhea at any time during treatment. You might not be able to take Kyprolis (carfilzomib) anymore.
Though uncommon, people taking Kyprolis (carfilzomib) have developed serious problems with their brain or nervous system. These problems can include posterior reversible encephalopathy syndrome (PRES) and progressive multifocal leukoencephalopathy (PML). Seek medical help right away if you have new severe headaches, confusion, seizures, severe weakness, or changes in your vision and speech. You might need to pause Kyprolis (carfilzomib) treatment while your provider looks into the problem.
In one study, certain people taking Kyprolis (carfilzomib) together with melphalan (Alkeran) and prednisone had higher rates of several serious side effects than those taking Velcade (bortezomib) with the same two medications. These side effects included heart problems, high blood pressure, kidney problems, and trouble breathing. Because of these results, this specific combination of medications isn’t recommended as first-choice treatment for some people with multiple myeloma. Talk to your provider if you’re unsure about your treatment regimen.
Based on findings from animal studies, Kyprolis (carfilzomib) might harm an unborn baby or raise the risk for miscarriage (pregnancy loss) if the medication is taken during pregnancy. For this reason, if you’re a female who can get pregnant, you should use birth control while you’re taking Kyprolis (carfilzomib) and for 6 months after the last dose. Consider using non-hormonal birth control to avoid raising your risk for blood clots. Males taking Kyprolis (carfilzomib) should use condoms if they have sex while taking the medication and during the 3 months after the last dose. Let your provider know right away if you become pregnant while taking Kyprolis (carfilzomib).
The dose is based on your body surface area (BSA, m2 units), which is calculated using your height and weight measurements. If your BSA is above 2.2 m2, your dose will be calculated using a BSA of 2.2 m2.
Kyprolis (carfilzomib) is given as an infusion through the veins (IV), usually once or twice a week. In general, the medication is given between weeks 1 and 3 in every 4-week treatment cycle.
For once-weekly dosing: The usual starting dose is 20 mg/m2 given IV once a week. After the first week, your provider might raise your dose to 70 mg/m2 once a week.
For twice-weekly dosing: The usual starting dose is 20 mg/m2 given IV twice a week. After the first week, your provider might raise your dose to either 27 mg/m2 or 56 mg/m2 twice a week.
Your dose and your treatment schedule will vary depending on whether you’re taking Kyprolis (carfilzomib) by itself or together with other medications for your cancer. Your dose might also differ if you have liver problems or have serious side effects from Kyprolis (carfilzomib).
Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are receiving this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.
Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.
Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.